The Role of Transoral Robotic Surgery in the Management of Oropharyngeal Cancer: A Review of the Literature

Table 2

Oncologic outcomes following TORS for OPSCC.

Study	Number of cases	Primary site	Pathological stage	HPV status	Followup period (mean)	Oncologic outcomes
Cohen et al. [13] (Apr ’10)	50	Oropharynx	T1/2: 39	HPV-neg: 13	HPV-neg: 23.0 mths	1 yr: 95.7% (45/47)
			T3: 11			2 yr: 80.6% (25/31)
				HPV-pos: 37	HPV-pos: 24.8 mths
			N0: 9
			N1: 21
			N2a: 0
			N2b: 20
			N2c: 0
			N3: 0
Genden et al. [20] (Aug ’11)	30	27 oropharynx (90%)	T1/2: 30/30	N/A	20.4 mths	18 mth:
		1 larynx (3.3%)				locoregional control: 91%
		1 oral cavity (3.3%)	N0: 6			distant control: 93%
		1 hypopharynx (3.3%)	N1: 10			DFS: 78%
			N2a: 5			OS: 90%
			N2b: 7
			N2c: 2
			N3: 0
Weinstein et al. [28] (Nov ’10)	47	Oropharynx	T1/2: 36	N/A	26 mths	Overall:
			T3/4: 11			1 yr: 96% (45/47)
						2 yr: 82% (27/33)
			N0: 1			DFS:
			N1: 24			1 yr: 96% (45/47)
			N2a: 1			2 yr: 79% (26/33)
			N2b: 19
			N2c: 2
			N3: 0
White et al. [29] (Dec ’10)	89	77 oropharynx (87%)	T1/2: 71	N/A	26 mths (median)	DFS (entire cohort)
		10 larynx (11%)	T3/4: 18			2 years: 86.3%
		2 oral cavity (2%)
			N0: 27			DFS (primary TORS cohort)
			N1: 8			2 years: 89.3%
			N2a: 11
			N2b: 26
			N2c: 12
			N3: 4